Skip to content
PeptideStack
New:Share your peptide stack →

Peptide News

Aggregated from PubMed, FDA, ClinicalTrials.gov, and industry sources.

This Week

KevinMD.com
The clinical evidence and reality of peptide therapy

The clinical evidence and reality of peptide therapy KevinMD.com

gq.com
Why Fitness Bros Are Buzzing About the New Weight-Loss Peptide Retatrutide

Why Fitness Bros Are Buzzing About the New Weight-Loss Peptide Retatrutide gq.com

retatrutide
The Times
This peptide serum has improved my skin in just one month

This peptide serum has improved my skin in just one month The Times

PubMed
The association between glucose dynamics and energy intake in young, healthy women.

Jin Z, Thackray AE, Willis SA. Eur J Clin Nutr

PubMed
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes.

Kim C, Bu F, Blacketer C. Nat Commun

RAPS
This Week at FDA: Makary reflects on first year, FDA working to lift peptide restrictions, and more

This Week at FDA: Makary reflects on first year, FDA working to lift peptide restrictions, and more RAPS

MSN
RFK Jr. eyes reversal of FDA peptide ban despite safety concerns

RFK Jr. eyes reversal of FDA peptide ban despite safety concerns MSN

ProPublica
RFK Jr. May Reverse a Peptide Ban He Calls “Illegal.” Former FDA Officials Say He Mischaracterized Their Work.

RFK Jr. May Reverse a Peptide Ban He Calls “Illegal.” Former FDA Officials Say He Mischaracterized Their Work. ProPublica

PubMed
Editorial: Two for the Price of One-GLP-1 Receptor Agonists Could Be More Effective Than MAUD in Patients With AUD and Metabolic Dysfunction.

Fozouni L, Im GY. Aliment Pharmacol Ther

PubMed
An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation.

Standen EC, Phelan SM, Tomiyama AJ. Int J Obes (Lond)

PubMed
Resistant starch-enriched rice varieties improve glucose homeostasis in diabetic mice via modulation of the intestine-liver-pancreas axis.

Zeng J, Li P, Chen H. NPJ Sci Food

PubMed
GLP-1 and GIP Drugs Before Endoscopy May Raise Residual Gastric Volume Risk.

Anderer S. JAMA

PubMed
Sex-specific metabolic responses to glucagon receptor agonism and modulation of the FGF21-glucagon axis in female mice.

Merrild C, Johansen VBI, Clemmensen C. J Physiol

PubMed
GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence.

Frey C. Future Oncol

PubMed
Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes.

Strickler I, Jensen A, Cragg K. J Am Acad Orthop Surg

PubMed
Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists.

Kubota S, Seino Y, Yabe D. J Diabetes Investig

Stocktwits
HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides

HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides Stocktwits

ClinicalTrials.gov
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (NCT07276373)

Phase: PHASE1 | Status: RECRUITING

ClinicalTrials.gov
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC (NCT06863311)

Phase: PHASE2 | Status: RECRUITING

ClinicalTrials.gov
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (NCT02595944)

Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (NCT06064097)

Phase: PHASE2 | Status: RECRUITING

ClinicalTrials.gov
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007)

Phase: PHASE2 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer (NCT06732401)

Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (NCT03907475)

Phase: PHASE2 | Status: RECRUITING

ClinicalTrials.gov
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (NCT03233711)

Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (NCT01895764)

Phase: PHASE4 | Status: COMPLETED

ClinicalTrials.gov
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (NCT04871191)

Phase: PHASE3 | Status: RECRUITING

ClinicalTrials.gov
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (NCT01829568)

Phase: PHASE1 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (NCT03604978)

Phase: PHASE1 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (NCT04267848)

Phase: PHASE3 | Status: RECRUITING

ClinicalTrials.gov
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (NCT02834013)

Phase: PHASE2 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (NCT07504588)

Phase: PHASE2 | Status: NOT_YET_RECRUITING

ClinicalTrials.gov
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (NCT00843882)

Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (NCT06991738)

Phase: PHASE1 | Status: NOT_YET_RECRUITING

ClinicalTrials.gov
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (NCT04929028)

Phase: PHASE2 | Status: ACTIVE_NOT_RECRUITING

ClinicalTrials.gov
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (NCT05985681)

Phase: PHASE1 | Status: RECRUITING

ClinicalTrials.gov
Prevalence and Influencing Factors of Frailty in Elderly Patients With Heart Failure (NCT07510035)

Phase: N/A | Status: COMPLETED

Endpoints News
The peptide fad lures health tech

The peptide fad lures health tech Endpoints News

openPR.com
Peptide Therapeutics Market (2026) | GLP-1 Drugs, FDA Approvals

Peptide Therapeutics Market (2026) | GLP-1 Drugs, FDA Approvals openPR.com

PubMed
GLP-1 Receptor Agonists.

Rosen CJ, Ingelfinger JR. N Engl J Med

WCVB
Understanding peptide injections

Understanding peptide injections WCVB

Endpoints News
Noom plans push into peptides beyond weight loss drugs

Noom plans push into peptides beyond weight loss drugs Endpoints News

Vox
Why the new GLP-1 pill is such a big deal

Why the new GLP-1 pill is such a big deal Vox

USA Today
RFK Jr. is 'a big fan' of peptides. What are they?

RFK Jr. is 'a big fan' of peptides. What are they? USA Today

Northeast Valley News
Some social media influencers promote peptide use for enhanced health or anti-aging—but scientists warn, “where is the evidence?”

Some social media influencers promote peptide use for enhanced health or anti-aging—but scientists warn, “where is the evidence?” Northeast Valley News

FDA
FDA Approves First New Molecular Entity Under National Priority Voucher Program

The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.

statnews.com
Pharmalittle: We're reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more

Pharmalittle: We're reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more statnews.com

PubMed
Rationally designed peptides relieve ischemic stroke by targeting TRPM2 intramolecular interactions.

Yao J, You Q, Liu X. Pharmacol Res

PubMed
Disparities in GLP-1 and GIP responses to small intestinal glucose infusion in individuals with well- and poorly-controlled type 2 diabetes.

Sun Y, Xie C, Bound M. Diabetes Res Clin Pract

PubMed
The evolving landscape of pathologic interpretation in metabolic dysfunction-associated steatotic liver disease.

Allende D. Hum Pathol

PubMed
GLP-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review.

Volkow ND, Xu R. Biol Psychiatry

PubMed
Semaglutide as a potential tool in pre-lung transplant weight loss optimization.

Ali R, Keyt H, Solis-Herrera C. JCEM Case Rep

semaglutide